The estimated Net Worth of David Price is at least $1.4 million dollars as of 1 September 2009. David Price owns over 150,000 units of Cortexyme Inc stock worth over $341,509 and over the last 16 years David sold CRTX stock worth over $1,057,500.
David has made over 1 trades of the Cortexyme Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently David sold 150,000 units of CRTX stock worth $1,057,500 on 1 September 2009.
The largest trade David's ever made was selling 150,000 units of Cortexyme Inc stock on 1 September 2009 worth over $1,057,500. On average, David trades about 21,429 units every 0 days since 2008. As of 1 September 2009 David still owns at least 175,133 units of Cortexyme Inc stock.
You can see the complete history of David Price stock trades at the bottom of the page.
David's mailing address filed with the SEC is C/O CORNERSTONE THERAPEUTICS INC., 2000 REGENCY PARKWAY, SUITE 255, CARY, NC, 27518.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi et Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: